VC/PE  Bain Capital Life Sciences g-innovation-life-sciences

     Office Locations:

200 Clarendon St.
Boston, MA 02116
Phone: 617-516-2000



  • Early
  • Expansion
  • Growth
  • Middle Market



  • Life Sciences & Healthcare
  • Medical Device



    Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. Bain Capital Life Sciences targets four types of investment opportunities: Engagement with companies at the critical development stages of innovation; Partnering with companies to accelerate and expand platforms; Engaging with companies at a crossroads to create value; and Collaborating with the Bain Capital platform to invest in and support larger companies

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Adam M. Koppel Managing Director
    Andrew Hack Managing Director
    Jeffrey Schwartz Managing Director


    Recent Funding Events (trailing 12 months):







      Amylyx Pharmaceuticals



      Series C





      Series B


      Xilio Therapeutics



      Series C


    Portfolio companies include:


    Recent News: